ClinicalTrials.gg
CompletedNCT00802841LASORUpdated Nov 16, 2015Results posted

Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib

A Phase 3 interventional study of nilotinib and imatinib in Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 56 sites in 12 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2015-11-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
191
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
12th of 66
191 · median 55
Started
2009
with 7 others
Phase 3
15 of 66
none open now
Registered
15th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 12th largest by enrollment, is one of 8 that started in 2009, is one of 15 in phase 3, and was the 15th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

There is no available data on the clinical benefit of dose escalation for patients with suboptimal response to imatinib, and patients may still improve their response with continuation of therapy at the standard dose as shown in the IRIS trial after 5 years of follow-up. However, there is no data yet regarding the potential benefit of using nilotinib in the group of patients with suboptimal response. In this study, the efficacy of nilotinib 400mg BID will be compared to imatinib 600mg QD.

Read the detailed description

The comparative efficacy between imatinib dose escalation (600 mg QD) and nilotinib (400 mg BID), in terms of CCyR after 6 months, for patients with CML in chronic phase with suboptimal response to imatinib standard dose will be determined.

03

Conditions studied

  • Chronic Myelogenous Leukemia

Keywords

  • Chronic
  • Myelogenous
  • Leukemia
  • CML
  • Chronic Phase
  • Suboptimal Response
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 years old;
  2. of 0, 1, or 2;
  3. Ph+ CML in CP defined as:

    • \<15% blasts in peripheral blood or bone marrow;
    • \<30% blasts + promyelocytes in peripheral blood or bone marrow;
    • \<20% basophils in the peripheral blood;

      •≥100x109/L (≥ 100,000/mm3) ;

    • no evidence of extramedullary leukemia involvement, with the exception of hepatosplenomegaly;
  4. SoR to 400 mg imatinib, defined as (min of 20 metaphases):

    • No cytogenetic response at ≥ 3 to \<6 months (> 95% Ph+ metaphases);or
    • No PCyR at ≥ 6 to \<12 months (36 to 95% Ph+ metaphases on bone marrow); or
    • No CCyR at ≥ 12 to \<18 months (1 to 35% Ph+ metaphases on bone marrow); Confirmation of SoR by FISH is allowed if BMK is done outside the screening window up to 4 wks.
  5. 400mg/daily imatinib (no higher doses) for at least 3months but no longer than 18 months;
  6. Previous use of IFN, taken prior to imatinib treatment, is allowed at a maximum of 90 days unless reason for switch from IFN to imatinib was intolerance.
  7. Parameters must be present:

    • Creatinine \<2.0 X
    • Total \<1.5 X ULN (\< 3.0 X ULN if related to disease);
    • and SGPT \< 2.5 X ULN;
    • Serum lipase ≤1.5 X ULN;
    • Alkaline phosphatase ≤2.5 X ULN
    • Serum potassium, phosphorus, magnesium and calcium ≥ LLN or corrected to WNL with supplements prior to first dose of study drug;
  8. Written prior to any study procedures being performed.

Exclusion criteria

Exclusion criteria:

  1. Prior accelerated phase including clonal evolution or blast crisis CML;
  2. Prior therapy with imatinib in combination with any other CML drug other than Hydroxyurea and/or Anagrelide;

4.Imatinib therapy started more than 12 months after the date of the original diagnosis; 5.Unable to tolerate imatinib at 400mg; 6.Previous treatment with any other tyrosine kinase inhibitor except Glivec and/or CML therapy other than IFN, hydroxyurea, and /or anagrelide; 7.Myelotoxicity ≥ Grade 2 present at the time of randomization, 8.Previously documented T315I mutations; 9.Impaired cardiac function including one of these:

  • Long syndrome or family history of long QT syndrome
  • resting brachycardia (\<50 bpm)
  • QTcF >450 msec on screening (using the QTcF formula). If QTc >450 and electrolytes are not with normal ranges, electrolytes should be corrected and then the patient rescreened for QTc to certify QTc \<450 msec;
  • Myocardial infarction ≤ 12 months prior to the first dose of study drug;
  • Other clinically significant heart disease (e.g., CHF, uncontrolled hypertension, unstable angina, significant ventricular or atrial tachyarrhythmias) 10. Impairment of GI function or disease that may significantly alter the absorption of study drug; 11. Treated with strong inhibitors that cannot be either discontinued or switched to a different medication prior to starting study drug; 12.Currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug; 13.History of previous acute pancreatitis within one year of study entry or medical history of chronic pancreatitis; 14.Known cytopathologically confirmed CNS 15.Women who are pregnant, breast feeding or of a without a negative urine pregnancy test at screening. Female patients of childbearing potential unwilling to use effective precautions throughout the trial and for 3 months post trial end. women must be ammenorrheic for at least 12 months to be considered of non-childbearing potential; 16. History of another primary that is currently clinically significant or currently requires active intervention; 17.Any other clinically significant medical or surgical condition which, according to investigators' discretion, should preclude participation; 18.Use of agent within 28 days prior to enrollment; 19.Patients unwilling or unable to comply with the protocol.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
191 participants (actual)

Study arms

  • Experimental
    Nilotinib

    Participants received 400 mg nilotinib twice daily (BID).

    Drug: nilotinib

  • Active comparator
    Imatinib

    Participants received 600 mg imatinib once daily (QD).

    Drug: imatinib

Interventions

  • Supplied as 200 mg tablets

    Also known as: Tasigna

  • Supplied as 100 mg and 400 mg tablets

    Also known as: Gleevec/Glivec

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Complete Cytogenetic Response (CCyR)

    CCyR was assessed from bone marrow samples. CCyr was defined as having 0% Philadelphia positive (Ph+) chromosome metaphases in bone marrow.

    Time frame: 6 months

Secondary outcomes

  1. Percentage of Participants With Major Molecular Response (MMR)

    MMR was defined as having a fusion gene of the Bcr and Abl genes of (BCR-ACL) less than or equal to 0.1% on the International Scale (IS).

    Time frame: 12 and 24 months

  2. Percentage of Participants With CCyr

    CCyR was assessed from bone marrow samples. CCyr was defined as having 0% Philadelphia positive (Ph+) chromosome metaphases in bone marrow.

    Time frame: 12 and 24 months

  3. Time to CCyR

    Time to CCyR was defined as time from date of randomization to date of first documented CCyR.

    Time frame: 24 months

  4. Duration of CCyR

    Duration of CCyR was defined as time from the date of ransomization to the date of first loss of CCyR or death, whichever came first.

    Time frame: 24 months

  5. Progression-Free Survival (PFS)

    PFS was defined as the time from the date of randomization to the date of documented disease progression to accelerated phase or blast crisis (AP/BC), or death due to any cause.

    Time frame: 24 months

  6. Event-Free Survival (EFS)

    EFS was defined as the time from the date of randomization to the date of the first occurrence of any of the following: loss of Complete Hematological Response (CHR), loss of Partial Cytogenetic Response (PCyR), loss of CCyR, death on treatment or progression to AP/BC.

    Time frame: 24 months

  7. Overall Survival (OS)

    OS was defined as time from date of randomization to the date of the death.

    Time frame: 24 months

07

Results

Posted Nov 16, 2015

Participant flow

Participants were randomized in 1:1 ratio to imatinib 600 mg QD or nilotinib 400 mg BID for a 2 year study period.

Participant flow — Overall Study
MilestoneNilotinibImatinib
Started9695
Full analysis set9695
Safety set9693
Cross-over set1356
Completed00
Not completed9695
Withdrew: Administrative problems10
Withdrew: Lost to follow-up21
Withdrew: Death12
Withdrew: Adverse event82
Withdrew: Disease progression73
Withdrew: Withdrawal by subject95
Withdrew: Protocol deviation26
Withdrew: Treatment duration completed6676

Outcome measures

PrimaryPercentage of Participants With Complete Cytogenetic Response (CCyR)

CCyR was assessed from bone marrow samples. CCyr was defined as having 0% Philadelphia positive (Ph+) chromosome metaphases in bone marrow.

Time frame:
6 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Cytogenetic Response (CCyR)
Percentage of participantsNilotinibImatinib
Percentage of Participants With Complete Cytogenetic Response (CCyR)50.042.1
Statistical analysis
  • Nilotinib vs Imatinib · Fisher Exact · p = 0.3106
SecondaryPercentage of Participants With Major Molecular Response (MMR)

MMR was defined as having a fusion gene of the Bcr and Abl genes of (BCR-ACL) less than or equal to 0.1% on the International Scale (IS).

Time frame:
12 and 24 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Major Molecular Response (MMR)
Percentage of participantsNilotinibImatinib
12 months36.525.3
24 months37.535.8
SecondaryPercentage of Participants With CCyr

CCyR was assessed from bone marrow samples. CCyr was defined as having 0% Philadelphia positive (Ph+) chromosome metaphases in bone marrow.

Time frame:
12 and 24 months
Reported as:
Number · Percentage of participants
Percentage of Participants With CCyr
Percentage of participantsNilotinibImatinib
12 months53.155.8
24 months51.061.1
SecondaryTime to CCyR

Time to CCyR was defined as time from date of randomization to date of first documented CCyR.

Time frame:
24 months
Reported as:
Median · Months
Time to CCyR
MonthsNilotinibImatinib
Time to CCyR5.55 (5.52 to 5.98)5.85 (5.59 to 11.04)
SecondaryDuration of CCyR

Duration of CCyR was defined as time from the date of ransomization to the date of first loss of CCyR or death, whichever came first.

Time frame:
24 months
Reported as:
Median · Months
Duration of CCyR
MonthsNilotinibImatinib
Duration of CCyRNA (NA to NA)17.2 (17.2 to NA)
SecondaryProgression-Free Survival (PFS)

PFS was defined as the time from the date of randomization to the date of documented disease progression to accelerated phase or blast crisis (AP/BC), or death due to any cause.

Time frame:
24 months
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsNilotinibImatinib
Progression-Free Survival (PFS)NA (NA to NA)NA (NA to NA)
SecondaryEvent-Free Survival (EFS)

EFS was defined as the time from the date of randomization to the date of the first occurrence of any of the following: loss of Complete Hematological Response (CHR), loss of Partial Cytogenetic Response (PCyR), loss of CCyR, death on treatment or progression to AP/BC.

Time frame:
24 months
Reported as:
Median · Months
Event-Free Survival (EFS)
MonthsNilotinibImatinib
Event-Free Survival (EFS)NA (NA to NA)24.3 (23.8 to NA)
SecondaryOverall Survival (OS)

OS was defined as time from date of randomization to the date of the death.

Time frame:
24 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsNilotinibImatinib
Overall Survival (OS)NA (NA to NA)25.7 (NA to NA)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib—11/96 (11.5%)80/96 (83.3%)
Imatinib—9/93 (9.7%)61/93 (65.6%)
Cross-over to Nilotinib—4/56 (7.1%)44/56 (78.6%)
Cross-over to Imatinib—1/13 (7.7%)11/13 (84.6%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventNilotinibImatinibCross-over to NilotinibCross-over to Imatinib
TachyarrhythmiaCardiac disorders0/960/930/561/13
ThrombocytopeniaBlood and lymphatic system disorders2/961/931/560/13
Angina pectorisCardiac disorders2/960/930/560/13
LymphadenopathyBlood and lymphatic system disorders0/960/931/560/13
PneumoniaInfections and infestations0/960/931/560/13
Blast cell crisisNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/961/931/560/13
Respiratory failureRespiratory, thoracic and mediastinal disorders0/960/931/560/13
EczemaSkin and subcutaneous tissue disorders0/961/931/560/13
Autoimmune thyroiditisEndocrine disorders1/961/930/560/13
Retinal detachmentEye disorders0/961/930/560/13
Most frequent other events
Showing 10 of 56
Most frequent other events
EventNilotinibImatinibCross-over to NilotinibCross-over to Imatinib
AnaemiaBlood and lymphatic system disorders11/9618/9310/564/13
HeadacheNervous system disorders14/966/938/564/13
ThrombocytopeniaBlood and lymphatic system disorders19/9624/9313/563/13
NeutropeniaBlood and lymphatic system disorders11/9623/9313/561/13
LeukopeniaBlood and lymphatic system disorders10/9622/939/560/13
VomitingGastrointestinal disorders4/9610/935/563/13
RashSkin and subcutaneous tissue disorders22/964/939/561/13
Alanine aminotransferase increasedInvestigations20/965/939/560/13
Blood bilirubin increasedInvestigations13/961/9311/560/13
DiarrhoeaGastrointestinal disorders6/9615/931/561/13

Baseline characteristics

Age, Continuous
Age, Continuous(Years)NilotinibImatinibTotal
Mean44.6 ± 14.4744.2 ± 15.0244.4 ± 14.75
Sex: Female, Male
Sex: Female, Male(Participants)NilotinibImatinibTotal
Female423779
Male5458112
08

Study locations

56 sites
  • Novartis Investigative Site
    Caba, Buenos Aires C1221ADC, Argentina
  • Novartis Investigative Site
    Caba, Buenos Aires C1426ANZ, Argentina
  • Novartis Investigative Site
    La Plata, Buenos Aires B1900AWT, Argentina
  • Novartis Investigative Site
    Rio Negro, Viedma 8500, Argentina
  • Novartis Investigative Site
    Belo Horizonte, MG 30130-100, Brazil
  • Novartis Investigative Site
    Cuiaba, MG 78025-000, Brazil
  • Novartis Investigative Site
    Curitiba, PR 80060-900, Brazil
  • Novartis Investigative Site
    Londrina, PR 86015-520, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, RJ 20211-030, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, RJ 20230-130, Brazil
  • Novartis Investigative Site
    Porto Alegre, RS 91350-200, Brazil
  • Novartis Investigative Site
    Florianopolis, SC 88034-000, Brazil
  • Novartis Investigative Site
    Campinas, SP 13083-970, Brazil
  • Novartis Investigative Site
    Jaú, SP 17210-080, Brazil
  • Novartis Investigative Site
    Sao Paulo, SP 05403-000, Brazil
  • Novartis Investigative Site
    São Paulo, SP 01224-000, Brazil
  • Novartis Investigative Site
    São Paulo, SP 05651-901, Brazil
  • Novartis Investigative Site
    São Paulo, SP 08270-070, Brazil
  • Novartis Investigative Site
    Nanjing, Jiangsu 210029, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Tianjin, Tianjin 300020, China
  • Novartis Investigative Site
    Beijing, 100044, China
  • Novartis Investigative Site
    Fuzhou, 350001, China
  • Novartis Investigative Site
    Shanghai, 200025, China
  • Novartis Investigative Site
    Bogota, Cundinamarca, Colombia
  • Novartis Investigative Site
    Monteria, Colombia
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Guatemala City, 01010, Guatemala
  • Novartis Investigative Site
    Hyderabad, Andhra Pradesh 500018, India
  • Novartis Investigative Site
    Bangalore, Karnataka 560 095, India
  • Novartis Investigative Site
    Vellore, Tamil Nadu 632004, India
  • Novartis Investigative Site
    Ahmedabad, 380016, India
  • Novartis Investigative Site
    Mumbai 400 020, 014, India
  • Novartis Investigative Site
    Mumbai, 400 012, India
  • Novartis Investigative Site
    New Delhi, 110 029, India
  • Novartis Investigative Site
    Mexico, Distrito Federal 06726, Mexico
  • Novartis Investigative Site
    México, Distrito Federal 02990, Mexico
  • Novartis Investigative Site
    México, Distrito Federal 06720, Mexico
  • Novartis Investigative Site
    México, Distrito Federal 14080, Mexico
  • Novartis Investigative Site
    Zapopan, Jalisco 45170, Mexico
  • Novartis Investigative Site
    Monterrey, Nuevo León 64020, Mexico
  • Novartis Investigative Site
    Panama City, Panamá, Panama
  • Novartis Investigative Site
    Kraków, 31-501, Poland
  • Novartis Investigative Site
    Wroclaw, 50-367, Poland
  • Novartis Investigative Site
    Ekaterinburg, 620102, Russian Federation
  • Novartis Investigative Site
    Krasnoyarsk, 680022, Russian Federation
  • Novartis Investigative Site
    Moscow, 125167, Russian Federation
  • Novartis Investigative Site
    Moscow, 129110, Russian Federation
  • Novartis Investigative Site
    N.Novgorod, 603126, Russian Federation
  • Novartis Investigative Site
    Perm, 614068, Russian Federation
  • Novartis Investigative Site
    Rostov-on-Don, 344090, Russian Federation
  • Novartis Investigative Site
    Saint-Petersburg, 197341, Russian Federation
  • Novartis Investigative Site
    St Petersburg, 191024, Russian Federation
  • Novartis Investigative Site
    Volgograd, 400138, Russian Federation
  • Novartis Investigative Site
    Caracas, Distrito Capital 1010, Venezuela
  • Novartis Investigative Site
    Maracaibo, Estado Zulia 4004, Venezuela
09

References and documents

Publications

  • Cortes JE, De Souza CA, Ayala M, Lopez JL, Bullorsky E, Shah S, Huang X, Babu KG, Abdulkadyrov K, de Oliveira JSR, Shen ZX, Sacha T, Bendit I, Liang Z, Owugah T, Szczudlo T, Khanna S, Fellague-Chebra R, le Coutre PD. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol. 2016 Dec;3(12):e581-e591. doi: 10.1016/S2352-3026(16)30167-3. PubMed 27890073 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2008
First posted
Dec 5, 2008
Start
May 2009
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Results first posted
Nov 16, 2015
Last update
Nov 16, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00802841
Responsible party
Sponsor
First posted
Dec 5, 2008
Start date
May 2009
Primary completion
Jul 2014
Completion
Jul 2014
Results posted
Nov 16, 2015
Last update
Nov 16, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion